Healthcare / Life Sciences EquipmentTechnical Analysis Guide

TMO Stock Analysis

Thermo Fisher Scientific Inc.

💡 Quick Answer

Across 4 APEX technical signals, TMO is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-07-08. Run a live analysis to see the current composite score.

TMO is considered the blue-chip compounder of healthcare. Consistent mid-to-high single-digit revenue growth with expanding margins.

RSI Behavior: Quality compounder 45-70Biopharma Capex Cycle: Order book leading indicatorMoving Average: 50-day defended in uptrends

Thermo Fisher is the world's leading life sciences equipment and services company, providing instruments, reagents, consumables, software, and services for scientific research, manufacturing, and clinical labs. Its four segments. Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products. Serve pharmaceutical, biotech, government, and academic customers globally. The pharma services segment manufactures drug substances for biopharma clients including GLP-1 drugs.

LIVE CHART·TMO. DailyPowered by TradingView

Open TMO on TradingView ↗Affiliate link

Get live TMO signal analysis

APEX runs 8 signals on TMO in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze TMO Now →

Why Do Traders Watch TMO?

TMO is considered the blue-chip compounder of healthcare. Consistent mid-to-high single-digit revenue growth with expanding margins. ATR of 2-3% makes it suitable for swing and position traders. It is a proxy for global biotech and pharma R&D spending: when biopharma capex rises, TMO's instrument and consumable orders follow. Post-earnings moves of 3-6% are reliable and tend to be directionally consistent with guidance.

Is TMO a Buy Right Now? Current Signal Readings

📊RSI BehaviorQuality compounder 45-70

TMO's RSI rarely dips below 40 during bull market phases, reflecting its consistent institutional demand. RSI pullbacks to 45-50 in uptrends have been among the most reliable entry signals in large-cap healthcare, typically resolving 10-15% higher over the subsequent 2-3 months.

📊Biopharma Capex CycleOrder book leading indicator

TMO's instrument order book and book-to-bill ratio are the best leading indicators for the global biopharma R&D cycle. When pharma companies increase R&D budgets. Visible in their quarterly calls. TMO orders accelerate within 1-2 quarters. This cycle played out perfectly in 2020-2022 and 2024.

📊Moving Average50-day defended in uptrends

Thermo Fisher's 50-day moving average has acted as institutional support in 9 of the last 10 bull-market corrections. The stock rarely requires a 200-day test during healthy market environments, making 50-day bounces the primary swing entry setup.

📊GLP-1 ManufacturingWeight loss drug tailwind

TMO's pharma services division manufactures active pharmaceutical ingredients for GLP-1 weight-loss drugs (Ozempic, Wegovy competitors). As GLP-1 demand scales to global markets, TMO's CDMO (contract drug manufacturing) revenue is expected to grow 15-20% annually through 2027. A durable secular growth driver independent of the instrument cycle.

📋 TMO Key Stats for Traders

⚡ATR (14-day)2-3% of price

📦Avg daily volume~2-4 million shares

🎯Key metricOrganic revenue growth + order book

📅Post-earnings move3-6% typical

🔗 Related Stocks

IDXX ABTADHR

Run a live TMO analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze TMO Free →

Advanced charting for TMO on TradingView ↗

💬 Frequently Asked Questions. TMO

QIs TMO a good stock to buy right now?

AWhether TMO is a buy depends on its current technical positioning. TMO is considered the blue-chip compounder of healthcare. Consistent mid-to-high single-digit revenue growth with expanding margins. ATR of 2-3% makes it suitable for swing and position traders. It is a proxy for global biotech and pharma R&D spending: when biopharma capex rises, TMO's instrument and consumable orders follow. Post-earnings moves of 3-6% are reliable and tend to be directionally consistent with guidance. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for TMO?

AThe four key signals for TMO are: RSI Behavior (Quality compounder 45-70). TMO's RSI rarely dips below 40 during bull market phases, reflecting its consistent institutional demand. RSI pullbacks to 45-50 in uptrends have been among the most reliable entry signals in large-cap healthcare, typically resolving 10-15% higher over the subsequent 2-3 months.. Biopharma Capex Cycle (Order book leading indicator). TMO's instrument order book and book-to-bill ratio are the best leading indicators for the global biopharma R&D cycle. When pharma companies increase R&D budgets. Visible in their quarterly calls. TMO orders accelerate within 1-2 quarters. This cycle played out perfectly in 2020-2022 and 2024.. Moving Average (50-day defended in uptrends). Thermo Fisher's 50-day moving average has acted as institutional support in 9 of the last 10 bull-market corrections. The stock rarely requires a 200-day test during healthy market environments, making 50-day bounces the primary swing entry setup.. GLP-1 Manufacturing (Weight loss drug tailwind). TMO's pharma services division manufactures active pharmaceutical ingredients for GLP-1 weight-loss drugs (Ozempic, Wegovy competitors). As GLP-1 demand scales to global markets, TMO's CDMO (contract drug manufacturing) revenue is expected to grow 15-20% annually through 2027. A durable secular growth driver independent of the instrument cycle.

QWhat is TMO's RSI telling traders right now?

ATMO's RSI rarely dips below 40 during bull market phases, reflecting its consistent institutional demand. RSI pullbacks to 45-50 in uptrends have been among the most reliable entry signals in large-cap healthcare, typically resolving 10-15% higher over the subsequent 2-3 months. APEX scores TMO's RSI as part of its 8-factor composite signal. Updated daily.

QHow does TMO behave technically compared to other Healthcare / Life Sciences Equipment stocks?

ATMO is in the Healthcare / Life Sciences Equipment sector. Thermo Fisher is the world's leading life sciences equipment and services company, providing instruments, reagents, consumables, software, and services for scientific research, manufacturing, and clinical labs. Its four segments. Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products. Serve pharmaceutical, biotech, government, and academic customers globally. The pharma services segment manufactures drug substances for biopharma clients including GLP-1 drugs. Key stats: ATR (14-day): 2-3% of price, Avg daily volume: ~2-4 million shares, Key metric: Organic revenue growth + order book, Post-earnings move: 3-6% typical.

QWhat MACD signals work best for TMO?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks TMO's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−